Drug Cut Skin Cancers After TransplantMedPage TodayNote that in this study, switching from calcineurin inhibitors to sirolimus had an anti-tumoral effect over a 2-year period among kidney-transplant recipients with previous squamous-cell carcinoma. ……
Immunosuppressant Switch Cuts Skin Cancer Post-TransplantRenal and Urology NewsIn kidney-transplant patients with at least one cutaneous squamous-cell carcinoma, switching immunosuppressants (from calcineurin inhibitors to sirolimus) is associated with…
Larger Kidneys Increase RCC Death RiskRenal and Urology NewsIn a study of 191 patients with pT1 RCC who underwent radical nephrectomy, investigators at Mayo Clinic reported that each 1-cm increment in kidney size (i.e., largest measured dimension) was …
PsychCentral.comWhy people don't perform under stressTimes of IndiaIn order to test the different stress hormones, the cognition psychologists used three substances – a placebo, the stress hormone hydrocortisone and yohimbine, which ensures that th…
The GuardianPregnant women more vulnerable to Hepatitis ETimes of IndiaIn one of the widest single-centre studies conducted by the All India Institute of Medical Sciences (AIIMS) here, it was found that water-borne Hepatitis E was the basic cause of ac…
PsychCentral.comWhy people don't perform well when stressedNewstrack IndiaIn order to test the different stress hormones, the cognition psychologists used three substances – a placebo, the stress hormone hydrocortisone and yohimbine, which ensures …
HOUSTON, July 26, 2012 /PRNewswire-USNewswire/ — While athletes from all over the world will be gathering in London for the 2012 Summer Olympics, hundreds of other athletes whose lives were saved by organ transplantation will gather to compete for th…
Cytokinetics Announces Heart Failure Program UpdateSYS-CON Media (press release)Based on the review of these data, the companies have selected oral formulations of omecamtiv mecarbil from this Phase I trial that warrant further evaluation in patients w…
Cytokinetics Announces Heart Failure Program UpdateMarketwire (press release)Based on the review of these data, the companies have selected oral formulations of omecamtiv mecarbil from this Phase I trial that warrant further evaluation in patients with…
Cytokinetics Announces Heart Failure Program UpdateMarketWatch (press release)Based on the review of these data, the companies have selected oral formulations of omecamtiv mecarbil from this Phase I trial that warrant further evaluation in patients wit…